GlassScriptPhysician profile
Hamid Nawaz
NPI 1932269503
$3,386.89
in general payments reported to CMS, 2019-2025
30 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.06 · 2021: $359 · 2022: $575 · 2023: $570 · 2024: $683 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888 · Travel and Lodging: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.51 |
| Travel and Lodging | $504.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $930.33 | 2021-2025 | |
| Boston Scientific Corporation | $860.50 | 2023-2025 | Watchman Access System, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.41 | 2021-2025 | Jardiance |
| Pfizer INC. | $254.33 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.83 | 2021-2025 | Lifevest |
| Abbott Laboratories | $86.58 | 2021-2024 | Cardiomems |
| Astellas Pharma US INC | $83.88 | 2022 | |
| Merck Sharp & Dohme LLC | $77.34 | 2021 | |
| Amgen INC. | $70.64 | 2019-2022 | |
| Daiichi Sankyo INC. | $63.74 | 2022-2023 | Injectafer |
| Edwards Lifesciences Corporation | $62.37 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Vertex Pharmaceuticals Incorporated | $53.86 | 2025 | |
| Dexcom, INC. | $49.87 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $43.08 | 2022-2024 | Brilinta |
| Janssen Pharmaceuticals, INC | $36.67 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $25.19 | 2023 | |
| Lantheus Medical Imaging, INC. | $23.57 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $23.05 | 2019 | |
| Heartflow, INC. | $19.75 | 2024 | |
| Sanofi-Aventis U.S. LLC | $18.40 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.86 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $16.00 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $14.59 | 2023 | Arcalyst |
| Lilly USA, LLC | $14.44 | 2025 | Zepbound, Mounjaro |
| Stryker Corporation | $14.10 | 2022 | |
| Kls-Martin L.P. | $14.01 | 2023 | |
| Bolton Medical INC | $13.82 | 2025 | Relay Thoracic Stent-Graft With Plus Delivery System, Treo Abdominal Stent-Graft System |
| Actelion Pharmaceuticals US, INC. | $13.65 | 2023 | Uptravi, Opsumit |
| La Jolla Pharmaceutical Company | $12.97 | 2023 | Giapreza |
| Medtronic, INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Nawaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.